About Invus
Invus is a private equity firm founded in 1985. It is primarily based in New York City, United States. As of Oct 2026, Invus is an active investor with a portfolio of 271 companies, comprising 271 funding rounds and 1 acquisition. In the last 12 months, it has participated in 27 funding rounds. The firm primarily invests in companies based in United States and United Kingdom. Its portfolio is spread across a wide range of sectors from Life Sciences to Enterprise Applications. Its latest investment was a $***** Series A round in Universal Quantum on Oct 08, 2026 which also saw participation from DCVC, Firgun Ventures and other investors.
A lot of funds co-invest with Invus, with names like Fidelity Investments sharing a substantial percentage of its portfolio.
Invus has a team of 55 people, including 17 partners.
Key Metrics
Founded Year
1985
Location
New York City, United States
Portfolio Sectors
Portfolio Locations
Acquisition Deals
Invus' Portfolio
Invus has a portfolio of 271 companies. They have invested in a total of 271 companies. Their most recent investment was in Universal Quantum (Series A round) on Oct 08, 2026. Here is the most recent investment by Invus:Date | Company | Round | Amount | Co-Investors |
|---|---|---|---|---|
Oct 08, 2026 | Series A | 5196 | ||
Oct 07, 2026 | Series B | 1528 | ||
Sep 24, 2026 | Series D | 5476 | ||
Sep 09, 2026 | Series F | 7976 |
Invus has acquired 1 company. Their most recent acquisition was of Ashley Stewart on Apr 01, 2024. Here is the most recent acquisition by Invus:
Acquisition Date | Company | Short Description | Total Funding | Founded Year |
|---|---|---|---|---|
Apr 01, 2024 | Retailer of plus-size women's apparel and accessories | $30.2M | 1991 |
Here is the portfolio snapshot of Invus:
Investments by Year
The maximum number of investments were made in 2021
Portfolio by Location
Companies are primarily in United States and United Kingdom
Portfolio by Sector
Companies are primarily in Life Sciences
Team profile of Invus
Invus has a team of 55 members including 17 Partners and 7 Principals located in United States, China and 2 more locations. Invus' team sits on the board of 4 companies.Here is a list of top team members in Invus:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | New York City | |||
Partner | - | - | ||
Partner | New York City | - | ||
Partner | New York City | |||
Partner | New York City | - | ||
Partner | New York City | |||
Partner | New York City | |||
Partner | New York City | - | ||
Partner | New York City | - | ||
Partner | New York City | - | ||
Partner | Hong Kong | - |
Co-investors of Invus
Over the past 41 years, 459 investors have co-invested in Invus's portfolio companies.
- Top Co-investors of Invus: 459 investors entered a company along with Invus. These include investors like Fidelity Investments (17 companies).
Invus News
•
Matchpoint Therapeutics Secures $150M Series B FundingMassinvestor•Oct 08, 2026•Nextech Invest, Invus, T1D Fund, BB Biotech and 5 others
•
Precision Neuroscience Secures $250M Series D Funding Led by Pershing Square Inc.Business Insider•Sep 24, 2026•Precision Neuroscience, PERSHING SQUARE, Invus, ARK Investment Management and 1 other
•
Pizza Bakery Owner Secures Capital Infusion from Artal Asia, an Invus Group AffiliateVCCircle•Sep 12, 2026•Invus, Artal Capital
•
Popo Global Raises Rs 532 Crore From Artal Asia for ExpansionViestories•Sep 11, 2026•Artal Capital, The Pizza Bakery, Invus
•
Agenus Secures $85 Million for Colorectal Cancer Clinical TrialInvesting•Jul 13, 2026•Commodore Capital, Agenusbio, TCG Crossover, Invus and 2 others
•
City Therapeutics Secures $99.5M Series B for RNAiVentureburn•Jun 09, 2026•City Therapeutics, NYBC Ventures, Regeneron Ventures, Rock Springs Capital and 6 others
•
Contraline Raises $92.5 Million Series B to Advance NES/T Male Contraceptive DevelopmentVentureburn•Jun 02, 2026•Invus, Contraline, Lumira Ventures, RA Capital Management and 4 others
•
Coultreon Biopharma Secures $125M Series A to Advance Immunology PipelineBioSpace•Apr 28, 2026•Novo Holdings, Forbion, Sofinnova Investments, Finchley Healthcare Ventures and 16 others
•
•
